Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Puoti M, Rockstroh JK, Klein MB, et al., eds. Clin Infect Dis. 2008;47(11):1468-1475.
Terrault NA, McCaughan GW, Curry MP, et al. International Liver Transplantation Society consensus statement on hepatitis C management in liver transplant candidates. Transplantation. 2017;101(5):945-955.
Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18(6):716-726.
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560‐1599.
Terrault NA, Zeuzem S, Di Bisceglie AM, et al. HCV-TARGET study group. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140.e5.
Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-1991.
Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu. Rev. Med. 2008;59:473-485.
Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and infants transmission study. J Infect Dis. 1998;177(6):1480-1488.
Thompson A, Zeuzem S, Rockstroh JK, et al. The combination of grazoprevir and elbasvir +RBV is highly effective for the treatment of GT1a-infected patients. The Liver Meeting 2015. 2015.
Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.
Tice JA, Chahal HS, Ollendorf DA. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Intern Med. 2015;175(9):1559-1560.
Tieu HV, Laeyendecker O, Nandi V, et al. Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City. PLoS One. 2018:13:e0200269.
Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2017;67(1):36-47. doi:10.1002/hep.29344.
Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology. 2018;67(1):36-47.
Torres HA, Mahale P. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. Liver Int. 2015;35(6):1661-1664.
Trooskin SB, Poceta J, Towey CM, et al. Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. J Gen Intern Med. 2015;30(7):950-957.
Turner SS, Gianella S, Yip MJ-S, et al. Shedding of hepatitis C virus in semen of human immunodeficiency virus-infected men. Open Forum Infect Dis. 2016;3(2).
Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013;58(2):538-545.